Pietro Ravani1,2, Robert Quinn3,2, Matthew Oliver4, Bruce Robinson5, Ronald Pisoni5, Neesh Pannu6, Jennifer MacRae3,2, Braden Manns3,2, Brenda Hemmelgarn3,2, Matthew James3,2, Marcello Tonelli3,2, Brenda Gillespie7. 1. Departments of Medicine and pravani@ucalgary.ca. 2. Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 3. Departments of Medicine and. 4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 5. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 6. Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada; and. 7. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND AND OBJECTIVES: People receiving hemodialysis to treat kidney failure need a vascular access (a fistula, a graft, or a central venous catheter) to connect to the blood purification machine. Higher rates of access complications are considered the mechanism responsible for the excess mortality observed among catheter or graft users versus fistula users. We tested this hypothesis using mediation analysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied incident patients who started hemodialysis therapy from North America, Europe, and Australasia (the Dialysis Outcomes and Practice Patterns Study; 1996-2011). We evaluated the association between access type and time to noninfectious (e.g., thrombosis) and infectious complications of the access (mediator model) and the relationship between access type and time-dependent access complications with 6-month mortality from the creation of the first permanent access (outcome model). In mediation analysis, we formally tested whether access complications explain the association between access type and mortality. RESULTS: Of the 6119 adults that we studied (mean age =64 [SD=15] years old; 58% men; 47% patients with diabetes), 50% had a permanent catheter for vascular access, 37% had a fistula, and 13% had a graft. During the 6-month study follow-up, 2084 participants (34%) developed a noninfectious complication of the access, 542 (8.9%) developed an infectious complication, and 526 (8.6%) died. Access type predicted the occurrence of access complications; both access type and complications predicted mortality. The associations between access type and mortality were nearly identical in models excluding and including access complications (hazard ratio, 2.00; 95% confidence interval, 1.55 to 2.58 versus hazard ratio, 2.01; 95% confidence interval, 1.56 to 2.59 for catheter versus fistula, respectively). In mediation analysis, higher mortality with catheters or grafts versus fistulas was not the result of increased rates of access complications. CONCLUSIONS: Hemodialysis access complications do not seem to explain the association between access type and mortality. Clinical trials are needed to clarify whether these associations are causal or reflect confounding by underlying disease severity.
BACKGROUND AND OBJECTIVES:People receiving hemodialysis to treat kidney failure need a vascular access (a fistula, a graft, or a central venous catheter) to connect to the blood purification machine. Higher rates of access complications are considered the mechanism responsible for the excess mortality observed among catheter or graft users versus fistula users. We tested this hypothesis using mediation analysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied incident patients who started hemodialysis therapy from North America, Europe, and Australasia (the Dialysis Outcomes and Practice Patterns Study; 1996-2011). We evaluated the association between access type and time to noninfectious (e.g., thrombosis) and infectious complications of the access (mediator model) and the relationship between access type and time-dependent access complications with 6-month mortality from the creation of the first permanent access (outcome model). In mediation analysis, we formally tested whether access complications explain the association between access type and mortality. RESULTS: Of the 6119 adults that we studied (mean age =64 [SD=15] years old; 58% men; 47% patients with diabetes), 50% had a permanent catheter for vascular access, 37% had a fistula, and 13% had a graft. During the 6-month study follow-up, 2084 participants (34%) developed a noninfectious complication of the access, 542 (8.9%) developed an infectious complication, and 526 (8.6%) died. Access type predicted the occurrence of access complications; both access type and complications predicted mortality. The associations between access type and mortality were nearly identical in models excluding and including access complications (hazard ratio, 2.00; 95% confidence interval, 1.55 to 2.58 versus hazard ratio, 2.01; 95% confidence interval, 1.56 to 2.59 for catheter versus fistula, respectively). In mediation analysis, higher mortality with catheters or grafts versus fistulas was not the result of increased rates of access complications. CONCLUSIONS: Hemodialysis access complications do not seem to explain the association between access type and mortality. Clinical trials are needed to clarify whether these associations are causal or reflect confounding by underlying disease severity.
Authors: Krishna Poinen; Robert R Quinn; Matthew J Oliver; Daniel Devoe; Rameez Kabani; Fareed Kamar; Priyanka Mysore; Adriane M Lewin; Swapnil Hiremath; Jennifer MacRae; Matthew T James; Lisa Miller; Brenda R Hemmelgarn; Louise M Moist; Amit X Garg; Tanvir T Chowdhury; Pietro Ravani Journal: J Am Soc Nephrol Date: 2016-10-06 Impact factor: 10.121
Authors: Kailash Jindal; Christopher T Chan; Clement Deziel; David Hirsch; Steven D Soroka; Marcello Tonelli; Bruce F Culleton Journal: J Am Soc Nephrol Date: 2006-03 Impact factor: 10.121
Authors: Pietro Ravani; Suetonia C Palmer; Matthew J Oliver; Robert R Quinn; Jennifer M MacRae; Davina J Tai; Neesh I Pannu; Chandra Thomas; Brenda R Hemmelgarn; Jonathan C Craig; Braden Manns; Marcello Tonelli; Giovanni F M Strippoli; Matthew T James Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Marcello Tonelli; Amit X Garg; Fabio Pellegrini; Pietro Ravani; Meg Jardine; Vlado Perkovic; Giusi Graziano; Richard McGee; Antonio Nicolucci; Gianni Tognoni; Giovanni F M Strippoli Journal: Ann Intern Med Date: 2010-06-24 Impact factor: 25.391
Authors: Joseph A Vassalotti; William C Jennings; Gerald A Beathard; Marianne Neumann; Susan Caponi; Chester H Fox; Lawrence M Spergel Journal: Semin Dial Date: 2012-04-04 Impact factor: 3.455
Authors: Thaminda Liyanage; Toshiharu Ninomiya; Vivekanand Jha; Bruce Neal; Halle Marie Patrice; Ikechi Okpechi; Ming-hui Zhao; Jicheng Lv; Amit X Garg; John Knight; Anthony Rodgers; Martin Gallagher; Sradha Kotwal; Alan Cass; Vlado Perkovic Journal: Lancet Date: 2015-03-13 Impact factor: 79.321
Authors: Pietro Ravani; Robert R Quinn; Matthew J Oliver; Divya J Karsanji; Matthew T James; Jennifer M MacRae; Suetonia C Palmer; Giovanni F M Strippoli Journal: Am J Kidney Dis Date: 2016-01-06 Impact factor: 8.860